XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
PerformanceObligation
Program
Apr. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Sep. 30, 2023
USD ($)
Installment
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Installment
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Accounts receivable, reserve for credit losses                 $ 0   $ 0   $ 0    
Vaxcyte, Inc.                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 22,500,000   22,500,000   17,500,000    
Nonrefundable, non-creditable upfront payment receivable                         $ 10,000,000    
Shares received | shares                         167,780    
Common stock fair value                         $ 7,500,000    
Payment received from definitive agreement $ 5,000,000                            
Regulatory milestones cash in payment                 $ 75,000,000   $ 75,000,000        
Number of installments | Installment                 2   2        
Additional milestone payment                 $ 60,000,000   $ 60,000,000        
Blackstone Life Sciences                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Upfront payment received   $ 140,000,000                          
BMS Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Number of programs advancing through preclinical development | Program               4              
Deferred revenue                 0   0   0    
2018 BMS Master Services Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 0   0   3,100,000    
2015 License Agreement | Blackstone Life Sciences | Royalty                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Upfront payment received   $ 140,000,000                          
Revenue interest percentage   4.00%                          
2018 Merck Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 0   $ 0   0    
Milestone payment receivable upon initiation of IND enabling toxicology study                             $ 15,000,000
2018 Merck Agreement | Merck Sharp & Dohme Corp                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Number of target programs | Program             2                
Initial transaction price             $ 60,000,000                
Contingent payment received                         10,000,000    
Milestone payment received                         2,500,000    
Additional milestone payment received                         7,500,000    
Revenue recognition aggregate contingent payments eligible to receive                           $ 500,000,000  
Milestone method revenue recognition description                     If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.        
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Upfront payment received           $ 5,000,000                  
Extended research term           1 year                  
2020 Merck Master Services Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 0   $ 0   0    
MDA Agreement | EMD Serono                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 0   0   0    
Supply Agreement | Vaxcyte, Inc.                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Reimbursements expenses accruals                 6,100,000   6,100,000   4,800,000    
Reimbursements expenses                 2,800,000 $ 4,000,000 5,600,000 $ 10,200,000      
Astellas License and Collaboration Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue                 74,600,000   74,600,000   86,100,000    
Number of target programs | Program     3                        
Upfront payment received                     90,000,000        
Transaction price     $ 90,000,000                        
Estimated service period     4 years                        
Recognition of up front payment     $ 89,100,000                        
Upfront payment revenue not recognized                     32,300,000        
Nonrefundable, non-creditable upfront payment receivable                         90,000,000    
Number of performance obligations | PerformanceObligation     4                        
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate                 422,500,000   422,500,000        
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Recognition of up front payment     $ 900,000                        
Tasly License Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Nonrefundable upfront payment receivable         $ 40,000,000                 40,000,000  
Maximum potential payments related to development regulatory commercialization contingent payments and milestones       $ 350,000,000 $ 345,000,000                 $ 345,000,000  
Minimum term of royalties receivable based on annual net sales         10 years                    
Reduction of research and development expenses recognized                 16,000 $ 0 $ 16,000 $ 0      
Initial licensing payment due       25,000,000                      
Initial licensing payment in escrow       $ 15,000,000                      
Upfront payment revenue recognized                         25,000,000    
Upfront payment withholding tax amount                         $ 2,500,000    
Revenue recognized from contingent payment                 5,000,000            
Income tax charge related to contingent payment                 500,000            
Maximum refund period on termination of study                     30 days        
Contingent payment recognized as deferred revenue                 5,000,000            
Withholding tax on deferred revenue                 $ 500,000